# Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients

> **NCT04840355** · — · RECRUITING · sponsor: **Guohui Li** · enrollment: 100 (estimated)

## Conditions studied

- Immune Related Adverse Events
- PD-1

## Interventions

- **DRUG:** Sintilimab Injection

## Key facts

- **NCT ID:** NCT04840355
- **Lead sponsor:** Guohui Li
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-26
- **Primary completion:** 2025-11-14
- **Final completion:** 2025-11-14
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04840355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04840355, "Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04840355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*